Not checkedNot checked for notices yet.
Use of genetically modified bacteria for drug delivery in humans: Revisiting the safety aspect
Udo Wegmann, Ana Lucia Carvalho, Martin Stocks and 1 more
Scientific Reports · 2017
doi:10.1038/s41598-017-02591-6 (opens in a new tab)
We email you when a new notice or a question about this paper appears.
Abstract
The use of live, genetically modified bacteria as delivery vehicles for biologics is of considerable interest scientifically and has attracted significant commercial investment. We have pioneered the use of the commensal gut bacterium Bacteroides ovatus for the oral delivery of therapeutics to the gastrointestinal tract. Here we report on our investigations of the biological safety of engineered B . ovatus bacteria that includes the use of thymineless death as a containment strategy and the potential for the spread of transgenes in vivo in the mammalian gastrointestinal tract. We demonstrate the ability of GM-strains of Bacteroides to survive thymine starvation and overcome it through the exchange of genetic material. We also provide evidence for horizontal gene transfer in the mammalian gastrointestinal tract resulting in transgene-carrying wild type bacteria. These findings sound a strong note of caution on the employment of live genetically modified bacteria for the delivery of biologics.
Abstract licence: CC BY-NC-ND
References30
30 more references, whose wording the paper’s licence keeps private.
Cited by papers we hold2
Reads
Read by people on this page
None yet.
Checked or read by AI through naulon
None yet.
A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.
Are you an author?
Is this your paper?
Claim it to add your note and be paid when agents cite it. Free.